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RESEARCH ARTICLE Open Access
Endometrial sampling in low-risk patients
with abnormal uterine bleeding: a
systematic review and meta-synthesis
Brenda F. Narice1* , Brigitte Delaney2 and Jon M. Dickson2
Abstract
Background: One million women per year seek medical advice for abnormal uterine bleeding (AUB) in the United
Kingdom. Many low-risk patients who could be managed exclusively in primary care are referred to hospital based
gynaecology services. Performing endometrial sampling (ES) in the community may improve care, reduce the rate
of referrals and minimise costs. We aimed to search and synthesise the literature on the effectiveness of ES (Pipelle
versus other devices) in managing AUB in low-risk patients.
Methods: We undertook an electronic literature search in MEDLINE via OvidSP, Scopus, and Web of Science for
relevant English-language articles from 1984 to 2016 using a combination of MeSH and keywords. Two reviewers
independently pre-selected 317 articles and agreed on 60 articles reporting data from over 7300 patients. Five
themes were identified: sample adequacy, test performance, pain and discomfort, cost-effectiveness, and barriers
and complications of office ES.
Results: Pipelle seems to perform as well as dilation and curettage and, as well or better than other ES devices
in terms of sampling adequacy and sensitivity. It also seems to be better regarding pain/discomfort and costs.
However, Pipelle can disrupt the sonographic appearance of the endometrium and may be limited by cervical
stenosis, pelvic organ prolapse and endometrial atrophy.
Conclusions: The current evidence supports the use of Pipelle in the management of low-risk women presenting
in the outpatient setting with symptomatic AUB when combined with clinical assessment and ultrasound scanning.
However, the implications of its widespread use in primary care are uncertain and more research is required.
Keywords: Pipelle, Endometrial sampling, Abnormal uterine bleeding, Endometrial cancer, Endometrial hyperplasia,
Premenopausal, Perimenopausal, Dilation and curettage
Background
Abnormal uterine bleeding (AUB), traditionally defined as
uterine bleeding that is abnormal in volume, regularity,
and/or timing [1] is common and affects 14–25% of women
of reproductive age [2–4]. In the UK, approximately 1 mil-
lion women seek medical advice for AUB every year, mostly
in general practice [5, 6] and even though most cases could
potentially be managed exclusively in primary care [7, 8],
AUB is the fourth most common reason for referral to UK
gynaecological services [6, 9, 10]. AUB has a major impact
on quality of life [7], leads to 3.5 million days of work
absence [11], and generates significant health care costs.
Hospital referrals and hysterectomies are the major compo-
nents of the £65 million/year treatment costs for AUB [10].
Most cases of AUB are benign and amenable to
office-based treatments [12, 13]. However, patients often
present with a myriad of symptoms, and their assess-
ment requires training and expertise [13, 14]. The causes
of AUB can be summarised using the PALM-COEIN
acronym: polyps, adenomyosis, leiomyoma/fibroids,
malignancy (and hyperplasia), coagulopathy, ovulatory
disorders, endometrial, iatrogenic, and not otherwise
classified [1].
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Some patients who present with AUB will have endo-
metrial hyperplasia or cancer which is the commonest
gynaecological malignancy in the Western world. Even
though the incidence rises after menopause, it can occur
at all ages and 7% of cases are under 50 [15, 16]. This
percentage seems to be rising with increasing prevalence
of obesity and diabetes [17, 18].
In the UK, women with AUB who are deemed at high
risk of endometrial cancer such as those with postmeno-
pausal bleeding (PMB) or family history of gynaeco-
logical neoplasms, should be referred to secondary care
[19]. For low-risk premenopausal women the guidance is
not as clear. Although urgent referral is not required
[20], national guidelines recommend that endometrial
sampling (ES) should be performed in women over 40–
45 years to exclude cancer [21, 22], but they do not
specify whether ES should be performed in primary or
secondary care [22].
In the UK, ES for AUB patients has not been tradition-
ally undertaken in primary care. For many years, the
standard management was dilation and curettage (D&C)
in hospital under general anaesthesia [23–25]. However,
the need for admission and the risks of perforation and
haemorrhage made D&C unpopular [23, 25] and various
ES devices were developed such as the Novak (a silastic
cannula with a bevelled lateral opening [26]), the
Tis-u-Trap (a plastic curette with suction [27]), the Vabra
Aspirator (a stainless steel cannula connected to a vacuum
pump [28]), the Endorette (a plastic cannula with multiple
openings [29]), the Tao Brush (a sheath brush device [30]),
the Cytospat (a polypropylene cannula with a rhomboid
head [31]), the Accurette (a quadrilateral-shaped curette
with four cutting edges [32]) and the Pipelle, the most
widely used device in the UK (a flexible plastic tube with a
distal circular port [27]).
We conducted a systematic review of the literature to
identify existing evidence about the effectiveness of Pipelle
compared with other ES techniques for assessing low-risk
women with AUB which could inform the development of
new care pathways in primary care.
Why this study was necessary
Endometrial sampling is thought to be a safe and effect-
ive method for histological assessment of the endomet-
rium. It is used as an alternative to the more invasive
method of D&C. This is the first review to focus on
AUB in low-risk pre- and perimenopausal women. We
conclude that ES is a valuable tool in the assessment of
these patients and that Pipelle is the best outpatient
device available. The evidence supports the use of Pipelle
in the outpatient setting but more research is required
to assess its impact if introduced as routine management
of AUB in the community.
Methods
Literature search
We used the PICO approach to develop a systematic search
strategy [33]. We searched MEDLINE via OvidSP, Scopus,
and Web of Science. For Medline, key concepts were iden-
tified (endometrial hyperplasia/cancer, abnormal uterine
bleeding, endometrial sampling), a list of synonyms was
generated for each concept and these lists were used to
identify MeSH terms for the search (Additional file 1).
Similar search strategies were used for Scopus and Web of
Science (Additional file 1), always limited to papers from
1984 (when Pipelle was first introduced [34]) to 2016, writ-
ten in English and involving humans.
We included papers investigating ES in women with
AUB. We also considered studies in patients with known
cancer; although these studies do not inform the indica-
tion of ES in primary care, they were an important source
to evaluate test performance. We included review articles
and opinion pieces. We excluded papers exclusively ana-
lysing postmenopausal patients, papers where the indica-
tion was assessment of fertility or recurrent miscarriage
and papers where ES was assisted by hysteroscopy (unless
this was used as a comparator to blind ES).
The initial search generated 173 results for Medline, 240
for Scopus, and 221 for Web of Science, totalling 634
search hits across all databases, 317 of which were
excluded for duplication. The remaining 317 articles were
assessed for inclusion using the titles and abstracts. The
assessment was independently repeated by a second
reviewer and a consensus was reached. After this process,
257 papers were excluded and the full text of 60 papers
were read. Twenty-two further papers were excluded
while another 22 papers were added from reference
search, giving a final list of 60 papers. This selection
included 16 randomized controlled trials (RCT), 26
prospective studies, 6 retrospective studies, 5 reviews, 2
meta-analyses, 1 survey, and 4 brief communications and
letters to the editor, which were included in the final ana-
lysis providing data over 7300 women (Fig. 1).
Bias risk assessment
The quality of the RCTs was assessed using the standard
Cochrane Risk of Bias tool [35], and the quality of obser-
vational studies was analysed with the modified Agency
for Healthcare Research and Quality (AHRQ) quality as-
sessment criteria [36].
Results
Risk of Bias / quality of studies
The overall quality of the RCTs was poor (n = 4) to
moderate (n = 12), no high quality studies were identified.
For observational studies, the risk of bias ranged from 31
to 79% with a mean weighted score 52.8% SD ± 11.8%
which again suggests overall moderate quality [37]. See
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additional online content for tabulated assessments of
individual studies (Additional file 2: TableS1 and 2,
Additional file 2).
Five themes
We identified five major themes in the literature: (1)
sample adequacy (defined as enough tissue to be analysed
by pathologists [38]); (2) test performance when compared
with hysterectomy and D&C; (3) acceptability by the
patient in terms of pain experienced during sampling; (4)
the costs of taking outpatient endometrial biopsies; and
(5) the barriers and complications of performing office ES.
All studies, except for one, were carried out in specialised
outpatient gynaecology clinics or hospital services (second-
ary care) [39]. Only one study looked exclusively at pre-
menopausal women [40]. The rest reported on cohorts of
both pre- and post-menopausal women or they did not
present results based on menopausal status. Most studies
included women with symptomatic AUB and no risk of
endometrial carcinoma. However, five studies targeted
women with endometrial cancer to correlate pre-operative
Pipelle with the hysterectomy histopathology [41–45].
Studies are summarised in Table 1.
Sample adequacy
Overall, the literature showed that the adequacy of mater-
ial retrieved for histological analysis with Pipelle was com-
parable to D&C and superior to most of the other devices
in pre-menopausal women. Ten studies [23, 24, 46–53]
assessed Pipelle against D&C in premenopausal women,
reporting rates of adequacy ranging from 89.74% [51] to
98% [23, 24] (Table 1).
Fig. 1 PRISMA flow diagram for study selection
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Table 1 Comparison of the RCTs, prospective and retrospective studies included in this literature review. Papers have been grouped
by intervention/ comparator
Study Type of study Age of participants
(mean ± SD)
Intervention (n) vs
Comparator (n)
Outcome Pain Cost
Pipelle versus
D&C +/−
Hysterectomy
[23] Rauf
et al.
Pakistan
2014
RCT 46.3 ± 4.45 Pipelle (102) vs
D&C (101)
Adequacy
Pipelle 98%
D&C 100%
Pipelle less
painful
Pipelle
cheaper
[46] Liu et al.
China 2015
Prospective
Sequential
43.6 Pipelle vs D&C
(245)
Adequacy
Pipelle 91.02%
D&C 92.24%
Pipelle less
painful
N/A
[47]
Gungorduk
et al. Turkey
2013
Prospective Pipelle: 49.8 ± 6.1
D&C: 48.2 ± 6.5
Pipelle +
hysterectomy
(78) vs D&C +
hysterectomy
(189)
Adequacy
Pipelle 95%
D&C 96%
Concordance
Pipelle +
hysterectomy
62%
D&C +
hysterectomy
67%
Pipelle less
painful
Pipelle
cheaper
[48] Kazandi
et al.
Turkey
2012
Prospective
Sequential
48 ± 9.43 Pipelle +
hysterectomy
Vs
D&C +
hysterectomy
(66)
Adequacy
Pipelle 93%
D&C 96%
Concordance
Pipelle and
D&C 66%
Pipelle &
hysterectomy
64%
Pipelle less
painful
Pipelle
cheaper
[49] Demirkiran
et al. Turkey 2012
Prospective 45.3 Pipelle +
hysterectomy
(212) vs D&C +
hysterectomy
(161)
Adequacy
Pipelle 97%
D&C98%
Concordance
Pipelle and
D&C 84%
Pipelle &
hysterectomy
67%
D&C and
hysterectomy
80%
Pipelle less
painful
Pipelle
cheaper
[43] Sany et al.
UK 2011
Retrospective ? Pipelle +
hysterectomy
vs D&C +
hysterectomy
(total 191)
Concordance
Both techniques
78%
N/A N/A
[45] Daud et al.
UK 2011
Retrospective 55.7 ± 11.4 Pipelle ±
hysterectomy
(75) vs D&C ±
hysterectomy
(220)
Concordance
Pipelle +
hysterectomy
76%
D&C +
hysterectomy
86%
N/A N/A
[24] Fakhar et al.
Pakistan 2008
Prospective
Sequential
45.4 ± 7.2 Pipelle versus
(D&C) (100)
Adequacy
Pipelle 98%
D&C 100%
NPV for
endometrial
carcinoma
Pipelle 100%
N/A (both
techniques
under GA)
Pipelle
cheaper
[44] Huang Retrospective ? Pipelle + Concordance N/A N/A
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Table 1 Comparison of the RCTs, prospective and retrospective studies included in this literature review. Papers have been grouped
by intervention/ comparator (Continued)
Study Type of study Age of participants
(mean ± SD)
Intervention (n) vs
Comparator (n)
Outcome Pain Cost
et al. USA 2006 + Letter hysterectomy
(253) vs D&C +
hysterectomy
(93)
Pipelle and
hysterectomy
93.8% (low grade
cancer) & 99.2%
(high grade cancer)
D&C and
hysterectomy
97% (low grade
cancer)
& 100% (high
grade cancer)
[37] Macones
et al. 2006
[66] Machado
et al. Spain
2002
Retrospective Post-menopausal
(68)
Pre- or
peri-menopausal
(100)
Pipelle (168)
vs D&C (92) ±
Hysterectomy
(76)
Accuracy
Sensitivity 84.2%
Specificity 99.1%
N/A N/A
[51] Kavak et al.
Turkey 1996
Prospective 50.8 ± 7.8 Pipelle ± TVS
(78) vs D&C
(78)
Concordance
Sensitivity: 73%
(increased to 90%
with TVS)
Specificity: 100%
N/A N/A
[50] Ben-Baruch
et al. Israel 1993
Prospective Pre- and
post-menopausal
Pipelle (172)
vs D&C (97)
Adequacy
Pipelle 90.6%
D&C 68%
N/A N/A
[68] Sanam
et al. Iran 2015
Prospective > 35 Pipelle (130)
vs D&C (130)
Concordance
Pipelle and
D&C 94%
Adequacy
Pipelle 84.6%
D&C 90%
N/A Pipelle
cheaper
[75] Gordon
New Zealand
1999
Prospective 47.2 ± 1.8 Pipelle (100)
vs D&C or
hysterectomy
(n =?)
Adequacy
Pipelle 67%
N/A N/A
[69] Goldchmit
et al. Israel
1993
Prospective
Sequential
48.1 Pipelle and TVS
vs D&C (176)
Concordance
Pipelle & D&C
90% (increased
to 92% with TVS)
N/A N/A
[52] Abdelazim
et al. Turkey
2013
Prospective
Sequential
44.5 Pipelle vs
D&C (143)
Adequacy
Pipelle 97.9%
D&C 100%
NPV for
endometrial
polyp
Pipelle 89.6%
N/A N/A
[72] Shams
Pakistan 2012
Prospective
Sequential
47.94 Pipelle vs
D&C (50)
N/A Pipelle less
painful
Pipelle
cheaper
[53] Rezk et al.
Egypt 2016
Prospective Pipelle: 47.2 ± 3.8
D&C: 46.9 ± 4.1
Pipelle (270)
vs D&C (268)
Adequacy
No difference
(p˃0.05)
D&C less
painful
N/A
Pipelle versus
Vabra +/−
Hysterectomy
[54] Eddowes
et al. UK 1990
Prospective
Sequential
41.6 Pipelle vs Vabra
Aspirator (100)
Adequacy
Pipelle 88%
Vabra Aspirator
88%
Pipelle less
painful
Pipelle
cheaper
[55] Naim et al.
Malaysia 2007
RCT > 45 Pipelle (76) vs
Vabra Aspirator
Adequacy
Pipelle 73.3%
N/A Pipellle
cheaper
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Table 1 Comparison of the RCTs, prospective and retrospective studies included in this literature review. Papers have been grouped
by intervention/ comparator (Continued)
Study Type of study Age of participants
(mean ± SD)
Intervention (n) vs
Comparator (n)
Outcome Pain Cost
(71) Vabra 52.4%
[28] Kaunitz
et al. USA
1988
Prospective
Sequential
46 Pipelle vs
Vabra (56)
Adequacy
Pipelle & Vabra
91%
Concordance
Pipelle & Vabra
89%
Pipelle less
painful
Pipelle
cheaper
[56] Rodriguez
et al. USA 1993
RCT ? Pipelle (12) vs
Vabra (13) vs
Hysterectomy
(25)
Surface being
sampled:
Pipelle 4.2%
Vabra 41.6%
N/A N/A
Pipelle versus
Tao Brush+/−
Hysteroscopy
[30] Williams
et al. UK 2008
RCT Sequential Moderate risk:
45.2 (SE 0.26)
For moderate
risk Pipelle (34)
Tao Brush (29)
Adequacy
Both techniques
84%
No significant
difference for
premenopausal
Tao Brush
less painful
N/A
[57] Critchley
et al. UK 2004
RCT Moderate risk:
pre-menopausal
˃40 or < 40 with
risk for
endometrial
cancer
Low risk
Pipelle vs Tao
Brush
Moderate risk
(Total 326)
Low risk
(Total 157)
± hysteroscopy
± TVS
Successful
completion of
investigation:
Pipelle 85%
Adequacy of
sample with
Pipelle:
Moderate
risk 79%
Tao Brush
less painful
than Pipelle
Minimal
difference
[58] Yang et al.
USA 2003
Prospective
Sequential
24–86 Pipelle (79) vs
Tao Brush (79)
Factors affecting
sensitivity: tumour
size, type, location
within the uterus,
sampling
mechanism and
preparation
method
N/A N/A
[59] Del Priore
et al. USA 2001
RCT Sequential Pre-menopausal:
46
Post-menopausal:
61
Tao Brush vs
Pipelle (50)
Sensitivity:
Pipelle 86%
Tao Brush 95.5%
Specificity:
Both 100%
N/A Tao Brush
cheaper
than D&C
[60] Yang et al.
USA 2000
Prospective
Sequential
58 Tao Brush vs
Tao Brush +
Pipelle (25)
Adequacy
Tao Brush 98%
Pipelle 88%
Tao Brush
less painful
Comparable
Pipelle versus
Novak
[40] Henig et al.
USA 1989
RCT Pre-menopausal Pipelle (50)
Vs Novak (50)
Adequacy
Pipelle 94%
Novak 98%
Better tolerance
with Pipelle
N/A
[26] Stovall et al.
USA 1991
RCT Pipelle: 40
Novak: 44
Pipelle (149)
vs Novak (126)
Adequacy
Pipelle 87.2%
Novak 90.5%
Pipelle less
painful
Novak might
be cheaper
[61] Silver et al.
USA 1991
RCT
Sequential
28–76 1st Pipelle then
Novak (26) vs
1st Novak then
Pipelle (29)
Adequacy
Similar
Pipelle less
painful
N/A
Pipelle versus
Hysterectomy
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Table 1 Comparison of the RCTs, prospective and retrospective studies included in this literature review. Papers have been grouped
by intervention/ comparator (Continued)
Study Type of study Age of participants
(mean ± SD)
Intervention (n) vs
Comparator (n)
Outcome Pain Cost
[67] Guido
et al. USA
1995
Prospective
Sequential
61 Pipelle vs
Hysterectomy
(71)
Adequacy
Pipelle 97%
Concordance
Pipelle &
hysterectomy
83%
N/A N/A
[42] Ferry
et al. UK
1993
Prospective
Sequential
? Pipelle vs
Hysterectomy
(37)
Concordance
Pipelle &
hysterectomy
67%
N/A N/A
[41] G Zorlu
et al. Turkey
1994
Prospective
Sequential
51 Pipelle vs
Hysterectomy
(26)
Concordance
Pipelle &
hysterectomy
95%
Mild pain
and
discomfort
with Pipelle
N/A
Pipelle versus
Explora +/−
Accurette
[62] Leclair
et al. USA
2011
RCT Pipelle: 45.2 ± 7.3
Explora: 46.1 ± 7.7
Pipelle (37) vs
Explora (32)
Adequacy
Pipelle 91%
Explora 97%
No
differences
seen
N/A
[32] Lipscomb
et al. USA
1994
RCT N/A
Pre- and post-
menopausal
Pipelle (85) vs
Accurette (81)
vs Explora (82)
Adequacy
Pipelle 85.2%
Accurette 72.5%
Explora 85.4%
No
significant
difference in
pain score
N/A
Pipelle versus
Infant Feeding
Tube (IFT)
[63] Bhide
et al. UK 2007
Prospective ? Pipelle (29)
vs IFT (31)
Adequacy
Pipelle 73%
IFT 71%
Less pain
with IFT
N/A
Pipelle Mark 2
versus Pipelle
Mark 2 +
hysteroscopy
[71] Polena
et al. France
2006
Prospective
Sequential
50 Pipelle Mark
2 vs Pipelle
Mark 2 ±
hysteroscopy
(97)
Adequacy of
Pipelle Mark 2
88.7%
No difference
with
conventional
Pipelle
Slightly more
expensive
than
conventional
Pipelle
Pipelle versus
Tis-u-Trap
[27] Koonings
et al. USA
1990
RCT Pipelle: 42.9
Tis-u-trap: 42.3
Pipelle +
hysterectomy
(74) vs
Tis-u-trap +
hysterectomy
(75)
Adequacy
Pipelle 87.8%
Tis-u-trap 84%
Concordance
Pipelle &
hysterectomy
85%
Tis-u-trap &
hysterectomy
92%
N/A Pipelle
cheaper
Pipelle versus
Endorette
[29] Moberger
et al. Sweden
1998
RCT
Sequential
57.5 ± 11.5 Pipelle vs
Endorette
(152)
Adequacy and
concordance
No difference
No
significant
difference
N/A
Pipelle versus
Cytospat +/−
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Table 1 Comparison of the RCTs, prospective and retrospective studies included in this literature review. Papers have been grouped
by intervention/ comparator (Continued)
Study Type of study Age of participants
(mean ± SD)
Intervention (n) vs
Comparator (n)
Outcome Pain Cost
Hysterectomy
[31] Antoni
et al. Spain
1996
RCT 48.6 ± 9 Pipelle ±
hysterectomy
or D&C (191)
vs Cytospat ±
hysterectomy
or D&C (174)
Adequacy
Pipelle 75%
Cytospat 76%
Concordance
Pipelle: Benign
84%, Hyperplasia
71%, Malignancy
60%
Cytospat: Benign
82%, Hyperplasia
60%, Malignancy
60%
Better
tolerance
for Pipelle
Pipelle
cheaper
Pipelle versus
D&C +/−
Hysteroscopy
+/− TV US
[85] Tahir
et al. UK
1999
RCT 35 Inpatient:
Hysteroscopy
& D&C (200)
vs Outpatient:
Pipelle +/− TV
US +/−
Hysteroscpy
(200)
Adequacy
No difference
Concordance
Inpatient: 100&
Outpatient: 82&
More pain in
outpatient
N/A
Others
[73] Trolice
et al. USA
2000
RCT
Anaesthesia
for Pipelle
Lidocaine:
42.1 ± 11.9/
Saline:
44.9 ± 12.5
Lidocaine
(19) vs Saline
(22)
Significant
reduction of pain
with lidocaine
Less pain
with
intervention
N/A
[34] Cornier
France 1984
Brief
communication
Mostly
pre-menopausal
Pipelle (250)
No control
Useful for
histologic
dating of the
endometrium
Little
discomfort
Low cost
[74] Frishman
USA 1990
Letter in
response to
study [27]
N/A Pipelle versus
Tis-u-Trap
N/A N/A Pipelle
cheaper
[38] Mc
Cluggage
Northern
Ireland 2006
Review N/A Pipelle versus
other ES
Difficulties of
processing
outpatient
ES samples
N/A N/A
[79] Van Den
Bosch Belgium
2005
Prospective
sequential
Pre-menopausal:
41.6 ± 8.7
Post-menopausal:
59 ± 9.9
US before and
after Pipelle (99)
Thickness of the
endometrium
ET on average
0.4 mm less after
performing
Pipelle
N/A N/A
[76] Brandner
et al.
Germany
2000
Review N/A N/A Progression of
endometrial
lesions (potential
limitations for ES)
N/A N/A
[80] Dijkhuizen
et al. The
Netherlands
2000
Meta-analysis 39 studies
including
7914 patients
Different ES Pipelle is superior
to other ES for
diagnosing cancer/
hyperplasia
N/A N/A
[25] Cooper
et al.
USA 2000
Review N/A N/A Directed biopsy with
Hysteroscopy: most
accurate ES (not for
primary care)
N/A N/A
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Three studies compared the sample adequacy of Pipelle
and Vabra Aspirator [28, 54, 55]. One of these studies [55]
showed better rates for Pipelle (73.3% versus 52.4%, P
= 0.02) whereas the remaining two could not identify any
significant difference between both techniques (one study
reported 91% for both techniques [28] whereas the other
showed 89.79% for Vabra versus 88% for Pipelle [54], no P
values provided) (Table 1). We also found a RCT which
reported that Pipelle despite being equal or superior to
Vabra in terms of sample adequacy only assesses 4.2% of
the endometrium versus 41.6% with Vabra [56].
Five studies including mixed cohorts of pre- and post-
menopausal women compared sample adequacy between
Pipelle and Tao Brush [30, 57–60]. Despite one study
suggesting that Tao Brush bendable wire should improve
sampling of the uterine lateral walls when compared to
Pipelle more rigid structure, none of the studies showed
significant differences in premenopausal populations
[58] (Table 1).
Two studies [40, 61] also compared Pipelle to Novak
and found no statistically significant difference in terms
of adequacy of sample, which varied from 83 to 94% for
Pipelle and from 85 to 98% for Novak [40, 61] (Table 1).
Six additional studies did not find a significant difference
when comparing Pipelle with other less popular ES tech-
niques such as Explora [32, 62] (85.4–97% for Explora
versus 85.2–91% for Pipelle), Tis-u-trap [27] (88% for
Pipelle versus 84% for Tis-u-Trap P = 0.5), Endorette
Table 1 Comparison of the RCTs, prospective and retrospective studies included in this literature review. Papers have been grouped
by intervention/ comparator (Continued)
Study Type of study Age of participants
(mean ± SD)
Intervention (n) vs
Comparator (n)
Outcome Pain Cost
[14] Farquhar
et al.
New Zealand 1996
Survey 68 replies from
O&G consultants
(48% of all
contestants)
N/A Management of
menorrhagia in
primary care
N/A N/A
[78] Youssif et al.
Australia 1995
Review N/A N/A Effectiveness and
safety of Pipelle
N/A N/A
[77] Dantas et al.
Brazil 1994
Letter Nurses vs doctors
performing Pipelle
N/A Adequacy No
difference
N/A N/A
[82] Clark et al.
UK 2002
Systematic
review and
meta-analysis
Mixed pre- (21%)
and pos-
tmenopausal (79%)
Pipelle vs other
outpatient
techniques
Likelihood ratio of
endometrial cancer
when Pipelle is:
-ve: 0.1
+ve: 64.6
N/A N/A
[86] Ahonkallio
et al. Finland
2009
Prospective Range 47–52
Post ablation
Pipelle (57) Adequacy
29% failure If
endometrium
< 5 mm
5% failure if
endometrium
> 5 mm
N/A N/A
[81] Du et al.
China 2016
Review N/A N/A Most appropriate
ES devices for
endometrial
lesions
Little
discomfort
N/A
[64] Masood
et al. Pakistan
2015
Cross
sectional
Pre- and
post-menopausal
35–48
Pipelle (126)
vs no
comparator
Adequacy
Pipelle 96.82%
N/A Cost-effective
[39] Seamark
UK 1998
Prospective ≥40
42–74
Primary care
population
Pipelle (38) vs
no comparator
Adequacy
Pipelle 76%
N/A N/A
[70]Seto
UK 2016
Retrospective Pre-menopausal
46.1 ± 4.6
Post-menopausal
57.2 ± 8.1
Pipelle against
hysteroscopy
Positive predictive
value for
endometrial polyp
Pipelle
(pre-menopausal)
53.7%
N/A N/A
[65] Piatek
et al. Poland
2016
Retrospective Pre- and
post-menopausal
Pipelle (312) vs
no comparator
Adequacy
83.01%
N/A N/A
ES Endometrial sampling, AUB Abnormal uterine bleeding, RCT Randomized controlled trials, US Transvaginal ultrasound, N/A Non-applicable,? Unknown
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[29] (56% for Endorette versus 43% for Pipelle), infant
feeding tube [63] (73% for Pipelle versus 71% for IFT)
and Cytospat [31] (Pipelle 74.9% versus 75.9% for
Cytospat).
Three studies [39, 64, 65] assessed the ability of Pipelle
to retrieve enough tissue for histological analysis without
comparing it to other devices, and reported a success
rate of 76% in GP practices [39], and a range from 83.01
to 96.82% in secondary care [64, 65] (Table 1).
Test performance
Nine studies compared the histopathological diagnosis of
pre-operative Pipelle and D&C with the final results from
hysterectomy (the gold standard diagnostic technique for
uterine disorders) [41, 43–45, 47–49, 66, 67]. For Pipelle,
the sensitivity ranged from 62% [47] to 99.2% [44] and for
D&C sensitivity varied from 67% [47] to 100% [44]. One
of these studies applied Pipelle and D&C sequentially
before hysterectomy [48], while the rest were multi-arm
studies [41, 43–45, 47, 49, 66, 67] (Table 1).
At least 5 studies [43, 48, 49, 68, 69] also reported on
the concordance between Pipelle and D&C with values
that ranged from 66% [48] to 94% [68].
One retrospective study which compared Pipelle sam-
ples suggestive of endometrial polyps with subsequent
hysteroscopically-guided polypectomies reported Pipelle
had a positive predictive value of 55.3% for sampling
polyps in premenopausal women [70]. Pipelle has also
been reported to have 100% negative predictive value
(NPV) for endometrial carcinoma and hyperplasia [24]
and up to 99.2% NPV for endometritis and 89.6% for
endometrial polyps [52] (Table 1).
Pain / discomfort
Most studies included in this review performed ES on
awake patients, but only 23 studies formally assessed
patients’ pain using visual pain analogue scales and ques-
tionnaires (Table 1). A total of 15 studies reported that
most patients experienced minimal discomfort with
Pipelle [23, 26, 28, 31, 34, 40, 41, 46–49, 54, 61, 71, 72],
three did not find any significant difference between
Pipelle and Explora [32, 62] and Pipelle and Endorette
[29], three concluded that Tao Brush was better tolerated
than Pipelle [30, 57, 60] and one study showed less dis-
comfort when using an infant feeding tube as a prototype
[63]. A RCT also reported that paracervical lidocaine dur-
ing Pipelle may decrease pain when compared to placebo
[73] (Table 1).
Costs of outpatient endometrial sampling
A total of 17 studies assessed the cost-effectiveness of
Pipelle though none formally provided a health economic
analysis [23, 24, 26–28, 31, 47–49, 54, 55, 57, 60, 68, 71,
72, 74]. Some of the factors they considered when
assessing the total cost of ES were the need for general
anaesthesia and hospital admission [23, 72] and the cost
of operative hysteroscopy/ D&C following a failed office
ES or an inadequate sample [55]. Fifteen studies showed
Pipelle was cheaper than the alternative ES [23, 24, 26–28,
31, 47–49, 54, 55, 57, 68, 72, 74] and two did not find
significant differences between Pipelle and Pipelle Mark 2
[71], and Pipelle and Tao Brush [60]. Two studies
concluded that the Vabra was cheaper than Pipelle given
its multiple use [26] but when all costs were considered
including the need for follow-up for failed procedures, the
average cost of Pipelle per patient was approximately 30%
cheaper than the Vabra aspirator [55] (Table 1).
Barriers and complications to endometrial sampling in
primary care
Several limitations to successful ES were reported including
cervical stenosis and pelvic organ prolapse which hindered
the access to the uterine cavity [24, 75] as well as focal
endometrial pathology (e.g. endometrial polyps and sub-
mucosal fibroids) and endometrial atrophy which reduces
sample adequacy [30, 46, 69, 75, 76]. Lack of experience
was also linked to inadequate sampling with higher failure
rates seen in registrars (39%) than in consultants (25%), (P
= 0.13)) [75]. However, a study which compared sample
adequacy between nurses (83.3%) and doctors (80%), P >
0.05, concluded that with the right training the ability to
perform successful Pipelle is independent of professional
category [77].
While few complications have been associated with
Pipelle [73]. [78], mainly discomfort and false negative
results, a study showed that Pipelle makes the endomet-
rium approximately 0.4 mm thinner and creates echo-
genic spots which can be misinterpreted as sonographic
lesions if the ultrasound is not performed prior to ES
[79] (Table 1).
Discussion
Our aim was to search and synthesise the whole range
of literature on ES in AUB in low-risk patients to guide
further research and develop new evidence-based care
pathways in primary care. Overall, the evidence that we
have identified supports the use of ES in the outpatient
setting and is a valuable source for the development of
new care pathways in primary care.
To the best of our knowledge, this study is the first
systematic review to primarily focus on the role of ES in
assessing and managing AUB in low-risk women in the
outpatient setting [25, 78, 80–82]. The available evidence
shows that when Pipelle is combined with clinical
assessment and ultrasound findings, it becomes a valuable
tool for investigating AUB in low-risk women. Pipelle
seems to perform as well or better than any other ES
device in terms of sampling adequacy and sensitivity, with
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comparable results to D&C which for years was the stand-
ard technique for obtaining endometrial tissue in patients
with AUB [78]. Furthermore, Pipelle seems to be
cost-effective and better tolerated in terms of pain/dis-
comfort [83]. However, its use has shown to be limited by
cervical stenosis, pelvic organ prolapse and endometrial
atrophy [24, 75]. Since Pipelle causes changes in the endo-
metrium, it should not be performed before USS [79], and
if the ultrasound reports localised lesions, a hospital refer-
ral for a hysteroscopy-guided biopsy may prove more use-
ful than performing a blind Pipelle [84] given its limited
sensitivity for focal lesions [47, 70].
Despite our robust and thorough literature search, we
have noted some limitations in the available evidence. We
only identified one study which was conducted on a
primary care population by general practitioners [39] and
one study which looked exclusively at premenopausal pa-
tients [40] and therefore, our conclusions are mainly based
on studies which were carried out in either outpatient spe-
cialised clinics or hospital departments on a mixed cohort
of pre- and postmenopausal women. Many of the studies
that we identified were of poor or moderate methodo-
logical quality with wide-ranging inclusion and exclusion
criteria (see Additional file 2). This heterogeneity may
partly be responsible for the significant variability seen in
terms of the sensitivity and specificity of Pipelle for detect-
ing endometrial hyperplasia/cancer.
A meta-analysis was beyond the scope of this paper but
critical appraisal and analysis of pooled data from diagnos-
tic studies is an important next step in establishing the
utility of ES. Given the limited information about the true
test performance of ES in the community, it is not possible
for clinicians to quantify the risk of hyperplasia/cancer (or
other pathology) based only on ES. This is especially
pertinent when the sample result is normal but the patient
is still symptomatic; clinicians should then continue to
consider the possibility of false negative results e.g. undiag-
nosed cancer/hyperplasia in these patients.
Conclusions
The evidence we analysed suggests that performing ES in
the outpatient setting may allow effective management of
low-risk women with AUB in primary care without
referral to a hospital. But the false negative rate, health
economics and implications of such a change in practice
are still unknown and more research is required.
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